Review of the cardiovascular safety of COXIBs compared to NSAIDS. - Wikidata - wikimedia - TriplyDB

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

http://www.wikidata.org/entity/Q37178937

about

Mesotherapy versus Systemic Therapy in the Treatment of Acute Low Back Pain: A Randomized Trial.Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty Traumeel - an emerging option to nonsteroidal anti-inflammatory drugs in the management of acute musculoskeletal injuries.Development and optimization of polymeric self-emulsifying nanocapsules for localized drug delivery: design of experiment approach.Fast Green FCF Alleviates Pain Hypersensitivity and Down-Regulates the Levels of Spinal P2X4 Expression and Pro-inflammatory Cytokines in a Rodent Inflammatory Pain Model.

P2860

Q34186840-C13F8748-0B7C-44EC-87FC-A6218254686E Q34195997-2CDDA68A-7828-4675-84D7-908F529742D0 Q42724656-7D209020-42DA-43CC-A1E9-783D64D03798 Q53657390-6161C753-5E57-4B6D-B0F8-305F06337C4C Q55027191-4AE88C92-46D5-4C3E-A74A-91F26C7890F0

P2860

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

http://www.wikidata.org/entity/Q37178937

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

@en

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

@nl

type

label

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

@en

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

@nl

prefLabel

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

@en

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

@nl

P1433

Q37178937-DAFFCD38-D944-412B-B3B6-DA7B39EBCD0F

P1476

Q37178937-4B180DD9-2F10-4B84-880D-BB76DE755730

P2093

Q37178937-90D31E49-8C78-48A7-983A-0820044021C1

P275

Q37178937-7C152996-459A-43A4-A6DA-B33632139E77

P2860

Q37178937-03C82648-BD29-4950-8308-80CB421B4FDB

Q37178937-048DACF0-2F52-46D7-9CBE-CA83994F7E7C

Q37178937-0753876B-9076-46B3-B67F-CC55375E9252

Q37178937-1401DBBA-1BCB-4964-9569-B812240459AF

Q37178937-1964E3AF-69C7-41D9-8995-AC6D6891FA25

Q37178937-1E2F9175-9409-4D0B-B3F1-30FB8E0EC5AB

Q37178937-1FBB9008-9D52-47F9-802F-8A6FF00703CA

Q37178937-1FCD5ACD-333E-4C44-866E-5D77797F69E8

Q37178937-21A674CE-CB71-4E7B-A515-E33A48B2279D

Q37178937-227DE10B-CEAC-4478-8E28-43EC531F0745

P304

Q37178937-B477D200-C202-4830-881C-B310C91375B7

P31

Q37178937-01182345-9684-4006-88AC-022EE2291A1C

Q37178937-5E6A2560-08EF-4989-A0E9-51F5AB4FBE0F

P433

Q37178937-64245713-7F1F-4C26-9A14-2D6CF9373468

P478

Q37178937-0042310A-6ED9-417B-B360-42969986CFC6

P5008

Q37178937-6993AFC3-85C4-4D80-85C0-8504A2934467

P577

Q37178937-7FD67509-4D4A-49B5-ACC5-81E6BA945D4E

P698

Q37178937-F9274D33-7F62-4B8B-AE63-467A7104F8C7

P921

Q37178937-1D7ECB52-26D9-4668-8C64-80F3DE6BB586

Q37178937-1EC06E17-4510-48DD-85B8-AE36D6AF805F

Q37178937-A1F018F1-BD83-457E-BE47-807AA882FEB5

P932

Q37178937-7F63B28E-FFEE-4050-9CFC-C537826FAF5B

P1433

Cardiovascular Journal of Africa

P1476

Review of the cardiovascular safety of COXIBs compared to NSAIDS.

@en

P2093

I Moodley

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

Selective COX-2 inhibition improves endothelial function in coronary artery disease

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

P304

102-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18516356

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

cardiovascular disease

P932

3975213

http://www.w3.org/2001/XMLSchema#string